REVELATION BIOSCIENCES, INC. (REVB)
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc.
- 2.4%
- 12.8K
- 1.00
Float 538.50K · Signal8 dilution snapshot · Nov 5, 2026
The cost to borrow REVB shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 38.7%
- 1
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 12.8K sh |
| Oct 15, 2026 | 944 sh |
| Sep 30, 2026 | 226 sh |
| Sep 15, 2026 | 37 sh |
| Aug 31, 2026 | 83 sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 27, 2026 | 1 sh |
| Oct 26, 2026 | 273 sh |
| Oct 23, 2026 | 423 sh |
| Oct 22, 2026 | 496 sh |
| Oct 21, 2026 | 10.1K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 38.7% |
| Nov 13, 2026 | 38.7% |
| Nov 12, 2026 | 17.7% |
| Nov 11, 2026 | 35.4% |
| Nov 10, 2026 | 6.4% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for REVB: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 12,792 REVB shares were sold short (2.38% of a 539K-share float, 1.00 days to cover).